Cannabidiol

alkaloid · nervous · digestive · Oral · Transdermal · Inhaled

Cannabidiol, an alkaloid. Non-psychoactive phytocannabinoid — weak CB1/CB2 affinity but allosteric negative modulator of CB1; agonist at TRPV1… Oral half-life 2.5 d.

Non-psychoactive phytocannabinoid — weak CB1/CB2 affinity but allosteric negative modulator of CB1; agonist at TRPV1, 5-HT1A; modulator of GPR55, adenosine reuptake. FDA-approved (Epidiolex) for Dravet + Lennox-Gastaut + tuberous sclerosis seizures. Strong CYP2C19 + CYP3A4 inhibitor at therapeutic doses.

Pharmacokinetics

• Oral — t½ 2.5 d · F 6% · ka 0.8776 h⁻¹ · Vd 1300 L
• Inhaled — t½ 24 h · F 59% · ka 89.33 h⁻¹ · Vd 1300 L

Sources: PMID:30534073, PMID:17245363, PMID:15033394